Ecnoglutide (development code XW003) is a once-weekly GLP-1 receptor agonist developed by Sciwind Biosciences, with essentially all of its clinical program run in China. What makes it worth a monograph is not a second receptor — unlike the dual and triple agonists — but how it activates the single GLP-1 receptor it targets. Ecnoglutide is engineered as a cAMP-biased agonist. As of 2026 it is approved in China only — by the National Medical Products Administration (NMPA), first for type 2 diabetes in January 2026 and then for chronic weight management in March 2026, making it the world’s first approved cAMP-biased GLP-1 receptor agonist.[6] It remains unapproved by the FDA, EMA, or any regulator outside China, and it is not available in the United States. Here is a straight read of the mechanism and the human trial data.
What “biased agonism” actually means here
When a GLP-1 receptor is activated, it can drive more than one downstream signal. Two matter: the cAMP pathway, which is tied to the metabolic effects you want (insulin secretion, appetite suppression), and β-arrestin recruitment, which promotes receptor internalisation and can blunt sustained signaling. Ecnoglutide was selected to preferentially trigger cAMP while largely sparing β-arrestin. In the discovery work, it induced cAMP with an EC50 of about 0.018 nM but showed essentially no receptor internalisation (EC50 > 10 μM) — the signature of a cAMP-biased ligand — and in rodent models produced more pronounced weight loss than semaglutide.[1] A phase 1 study in healthy volunteers established a half-life at steady state of roughly 124–138 hours, which is what supports once-weekly subcutaneous dosing.[1]
Whether that in-vitro bias translates into a meaningful clinical advantage over conventional GLP-1 agonists is still an open question — the human trials so far establish efficacy, not superiority driven by the bias itself. For context on the plain GLP-1 benchmark, see our semaglutide weight-loss trials review, and for the receptor-stacking alternatives, our tirzepatide versus semaglutide comparison. Ecnoglutide is a bet on signaling quality at one receptor rather than on adding more receptors.
The phase 3 obesity trial
The headline weight data come from a randomized, double-blind, placebo-controlled phase 3 trial at 36 centers across China. It enrolled 664 adults with overweight or obesity (without type 1 or type 2 diabetes), randomized to once-weekly ecnoglutide at 1.2, 1.8, or 2.4 mg or matching placebo.[2]At week 40, the least-squares mean change in body weight was −9.1%, −10.9%, and −13.2% across the three ascending doses, versus +0.1% on placebo (all p < 0.0001).[2] The proportion losing at least 5% of body weight was 77%, 84%, and 87% versus 16% on placebo.[2]
Those magnitudes sit in the same range as approved once-weekly GLP-1 therapy, though cross-trial comparison is only suggestive — different populations, different durations. As with every incretin drug, the reduction includes lean as well as fat mass, and this was a 40-week efficacy study, not a long-term cardiovascular-outcomes trial. Treatment-emergent adverse events were common (about 93% on ecnoglutide versus 84% on placebo), dominated by mild-to-moderate gastrointestinal effects.[2]
The type 2 diabetes program
Ecnoglutide's diabetes evidence spans a phase 2 dose-finder and two phase 3 trials. In the phase 2 study, 145 adults with type 2 diabetes received 0.4, 0.8, or 1.2 mg weekly for 20 weeks; HbA1c fell by −1.81%, −1.90%, and −2.39% respectively versus −0.55% on placebo (p < 0.0001), and a third of the top-dose group lost at least 5% of body weight.[3] The phase 3 EECOH-1 monotherapy trial (211 participants, 32 Chinese centers) confirmed the pattern: at week 24, HbA1c dropped −1.96% (0.6 mg) and −2.43% (1.2 mg) versus −0.87% on placebo.[4]
The most informative diabetes trial is EECOH-2, a 52-week, open-label, active-controlled phase 3 study of 621 adults on metformin, randomized to ecnoglutide 0.6 or 1.2 mg or dulaglutide 1.5 mg. At week 32, HbA1c reductions were 1.91% and 1.89% with ecnoglutide versus 1.65% with dulaglutide — establishing non-inferiority for both doses, with the 1.2 mg dose reaching statistical superiority that the authors judged not clinically meaningful.[5] In plain terms: ecnoglutide performs at least as well as an established GLP-1 agonist on glucose control, which is the bar that matters for a new entrant.
Where it sits, and the honest caveats
Ecnoglutide belongs to the wave of next-generation incretin candidates being pushed out of China, alongside agents such as mazdutide, and it competes conceptually with the move toward oral GLP-1 dosing covered in our orforglipron oral GLP-1 evidence review. The distinguishing pitch is the cAMP bias and a reportedly simplified manufacturing process, not a novel weight-loss ceiling.
Three honest limits, updated for where things actually stand as of mid-2026. First, geography and sponsor: the entire efficacy dataset comes from Chinese trial populations funded by a single company, Sciwind Biosciences — a real evidence base, and one that has now cleared a real regulator, but a narrow one that has not been tested against the FDA or EMA. Second, tolerability: like all GLP-1 agonists, gastrointestinal adverse events are the dominant and dose-related issue.[2] Third, status: ecnoglutide is no longer purely investigational — it is an approved drug in China, cleared by the NMPA for type 2 diabetes and, months later, for chronic weight management, with Pfizer China partnering to commercialise it there.[6] But it is still not approved in the US, EU, or anywhere outside China, so any product sold as “ecnoglutide” to a US or EU buyer outside that market is unverified. The correct summary has shifted from “promising and unapproved” to a real approved GLP-1 drug with strong Chinese phase 3 data — available in China, with no US or EU approval yet.